Lenalidomide with rituximab for mantle cell lymphoma

Bookmark and Share
Published: 11 Dec 2017
Views: 3003
Prof Jia Ruan - Weill Cornell Medicine and New York Presbyterian Hospital, New York, USA

Prof Ruan speaks with ecancer at the ASH 217 annual meeting about 5 year follow-up data from a trial of immunomodulatory induction therapy for mantle cell lymphoma patients.

The median age among the 38 patients involved in this trial was 65.

She describes the results as consistent with existing safety, efficacy and survival data from a 2015 interim analysis, and describes the management of adverse events including infections and neutropenia.

Prof Ruan notes that, our of patients who developed secondary malignancies, skin diseases were the most common, and that a history of skin cancer was not an exclusion criteria for patients entering the trial so long as they were not receiving current therapies.

Overall, Prof Ruan looks forward to future trials incorporating immune therapies into new combinations to tackle MCL.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.